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Background: The p53 protein is expressed as multiple isoforms that differ in their N- and C-terminus due to
alternative splicing, promoter or codon initiation usage. Δ40p53 lacks the first 39 residues containing the main
transcriptional activation domain, resulting from initiation of translation at AUG +40 in fully spliced p53 mRNA or in
a specific variant mRNA retaining intron 2. Overexpression of Δ40p53 antagonizes wild-type p53 in vitro. However,
animal models of Δ40p53 in mouse or Zebrafish have shown complex phenotypes suggestive of p53-dependent
growth suppressive effects.
Methods: We have co-transfected expression vectors for p53 and Δ40p53 in p53-null cell lines Saos-2 and H1299
to show that Δ40p53 forms mixed oligomers with p53 that bind to DNA and modulate the transcription of a
generic p53-dependent reporter gene.
Results: In H1299 cells, co-expression of the two proteins induced a decrease in transcription with amplitude that
depended upon the predicted composition of the hetero-tetramer. In Saos-2, a paradoxical effect was observed,
with a small increase in activity for hetero-tetramers predicted to contain 1 or 2 monomers of Δ40p53 and a
decrease at higher Δ40p53/p53 ratios. In this cell line, co-transfection of Δ40p53 prevented Hdm2-mediated
degradation of p53.
Conclusion: Δ40p53 modulates transcriptional activity by interfering with the binding of Hdm2 to hetero-tetramers
containing both Δ40p53 and p53. These results provide a basis for growth suppressive effects in animal models co-
expressing roughly similar levels of p53 and Δ40p53.
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The p53 tumour suppressor protein, encoded by TP53
gene (OMIM 191170), integrates endogenous and exogen-
ous signals to modulate cell fate in response to multiple
forms of environmental and cellular stresses [1]. In re-
sponse to such stresses, the p53 protein escapes from
down-regulation by Hdm2/Hdmx, which bind in the N-
terminal region of p53, and acts as E3 ubiquitin ligase to
induce p53 nuclear export and degradation by the prote-
asome [2,3]. The resulting nuclear accumulation, combined
with multiple steps of post-translational modifications,* Correspondence: pierre.hainaut@i-pri.org
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reproduction in any medium, provided the orleads to the activation of sequence-specific DNA-binding
to response elements located in a wide panel of target
genes, resulting in transcriptional regulation of genes in-
volved in cell-cycle arrest, differentiation, DNA repair,
autophagy, apoptosis, senescence and control of oxidative
metabolism [4,5]. These multiple effects contribute to an
extensive repertoire of anti-proliferative biological re-
sponses. The type and degree of responses depend upon
which specific components of this repertoire are activated
in a manner that differs according to tissue, cell type, meta-
bolic context and nature of inducing stress [5,6]. Given
these multiple, complex effects, it is likely that p53 activity
is under extremely tight control and that several, overlap-
ping mechanisms may concur to set tissue- and cell-d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ent types of stimuli.
In recent years, the identification of isoforms of the p53
protein has provided a new mechanism that may con-
tribute to the fine-tuning of p53 activity. Isoforms are
produced by alternative splicing, alternative promoter or
codon initiation usage, or combinations thereof [7]. The
resulting proteins differ from canonical, full-length p53
protein, by truncation of a variable portion of the N-
terminus (ΔN isoforms) and by alternative C-terminal por-
tions (C-terminal isoforms). So far, up to 4 distinct N-
terminal and 3 C-terminal variants have been identified,
leading in theory to 12 isoforms (including full-length p53;
[8]). These isoforms retain at least part of the DNA bind-
ing and oligomerization capabilities, but differ through
regulatory domains in the N- and C-terminus, supporting
the notion that their main biological effect is to modulate
p53 protein functions. However, the existence, expression
patterns and detailed biological function of each particular
isoform is still poorly documented.
The Δ40p53 isoform is a form of the protein that lacks
the first 39 residues containing the main transactivation
domain (residues 1–42), as well as major activating
phosphorylation sites and the binding site for Hdm2, the
main regulator of p53 degradation [9,10]. Δ40p53 is
produced by two complementary mechanisms, alterna-
tive codon initiation usage at AUG 40 in fully-spliced
p53 mRNA, and alternative splicing that retains intron
2, which introduces stop codons downstream of the +1
AUG and leads to the synthesis of a truncated protein
using AUG 40 in exon 4 as initiation codon [11,12]. In
vitro studies have shown that Δ40p53 interferes with p53
transcriptional activity, acting as concentration-dependent
dominant inhibitor when artificially expressed in excess to
full-length p53 [9]. Two animal models overexpressing
Δ40p53 have been reported, one in the mouse [13,14]
and the other in Zebrafish [15]. Overexpression of a trans-
gene encoding a p44 protein corresponding to Δ40p53
(MD41p53) did not induce any specific phenotype in p53-
deficient mice. However, when expressed in a wild-type
Trp53 background, increased dosage of MD41p53 led to
reduced size, accelerated aging and a shorter lifespan asso-
ciated with hypo-insulinemia and glucose insufficiency
[13,14]. Compatible effects were observed in Zebrafish, in
which expression of Δ40p53 in a p53-null background did
not lead to a specific phenotype although expression in a
p53-competent background resulted in impaired growth
and development [15]. Overall, these results suggest that
Δ40p53 exerts its main biological effects by modulating
the activity of full-length p53. Furthermore, they suggest
that Δ40p53 exerts effects other than simple dominant-
negative inhibition of p53.
In this study, we have used biochemical approaches to
assess the effects of co-expression of Δ40p53 and full-length p53 at different ratio into p53-null human cancer
cell lines and we have analyzed the effects on p53 pro-
tein expression, DNA-binding capacity and transcrip-
tional activity towards a p53-dependent reporter gene.
Our results show that Δ40p53 exerts an inhibitory effect
when expressed in excess over full-length p53. However,
when expressed at levels inferior or equal to full-length
p53, Δ40p53 appears to exert more complex effects, ran-
ging from inhibition to activation of p53 transcriptional
activity, depending upon cellular context. These results
support the hypothesis that Δ40p53 is a critical regulator
of wild-type p53 function and provide a basis to inter-
pret the complex biological phenotypes induced by this
isoform in animal models.
Methods
Cell culture
Human breast cancer 21PT cells (gift of V. Band, [16])
were grown at 37°C in 5% CO2 in MEM with Earle’s
Salts medium (PAA, Linz, Austria) supplemented with
10% fetal bovine serum, 1% penicillin-streptomycin-
glutamine, 10 ng/ml Epidermal Growth Factor, 10 μM
hydrocortisone and 1 μg/ml human insulin. Human
colorectal HCT116 cells (gift of B. Vogelstein, [17])
were cultured at 37°C in 5% CO2 in Mc Coy’s 5A
medium modified (Invitrogen, Carlsbad, CA, USA)
supplemented with 10% of fetal bovine serum and 1% of
penicillin-streptomycin-glutamine. Human lung carcin-
oma H1299 cells (p53-null) (ATCC N°CRL-5803) were
grown at 37°C in 5% CO2 in RPMI-1640 medium (PAA)
supplemented with 10% fetal bovine serum and 1%
penicillin-streptomycin-glutamine. Human osteosarcoma
Saos-2 cells (p53-null) (ATCC N°HTB-85) were grown
at 37°C in 5% CO2 in Mc Coy’s 5A medium modified
(Invitrogen) supplemented with 15% fetal bovine serum and
1% penicillin-streptomycin-glutamine. Mouse embryonic
fibroblast BALB/c 10.1 cells (p53-null) (ATCC N°CCL-163)
were grown at 37°C in 5% CO2 in Dulbecco’s Modified
Eagle’s Medium (PAA) supplemented with 10% of fetal bo-
vine serum and 1% of penicillin-streptomycin-glutamine.
Expression vectors, transfections and reporter gene
assays
Expression vectors pcDNA3-TAp53 (mut40) and pcDNA3-
Δ40p53, based on the pcDNA3.1 vector (Invitrogen) contai-
ning the Cytomegalovirus (CMV) enhancer-promoter, which
is constitutively active and drives high levels of mRNA ex-
pression in human cells, were described previously [9,18].
The pcDNA3-TAp53 (mut40) plasmid contains a muta-
tion at codon ATG 40 (ATG > TTG) to prevent Δ40p53
expression by internal initiation of translation. The plas-
mid pCMV-Neo-Bam-Hdm2 was kindly provided by J.C.
Marine [19]. The pcDNA3-empty vector was used as
negative control as well as adjustment vector in dose-
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amount of transfected DNA to a constant level. Depend-
ing upon the cell lines used, transfections were performed
using Fugene (Promega, Fitchburg, WI, USA) (H1299 and
Saos-2 cells) or Lipofectamine 2000 (Invitrogen) (BALB/c
10.1 cells).
Cycloheximide treatment
In 60 mm dishes, 4 × 105 HCT116 p53+/+ and 21PT cells
were treated with 50 μg/ml of cycloheximide (Sigma
Aldrich, St Louis, MO, USA).
Co-immunoprecipitation assay
In 100 mm dishes, 2 × 106 BALB/c 10.1 cells were trans-
fected using Lipofectamine 2000 with 2 μg/ml of
pcDNA3-expression vectors (empty, -TAp53, -Δ40p53).
Different ratios of the two pcDNA3-expression vectors
TAp53/Δ40p53 were transfected (0.5/0.5 and 1.5/0.5 μg/ml).
The total amount of plasmid was adjusted by adding
empty vector to reach 2 μg/ml. Cells were lysed 24 h post-
transfection by adding 250 μl of lysis buffer (10 mM Tris
pH 7.5, 140 mM NaCl, 0.5% Triton, 2 mM DTT, 1 mM
EDTA and 1 tablet of protease inhibitor cocktail/10 ml
Complete Mini, Roche). Total protein extracts (500 μg)
were cleared by incubation (4°C-1 h) with 25 μl of anti-
mouse sepharose beads (Sigma) and then incubated (4°C-
overnight) with p53 mouse monoclonal DO-7 antibody,
which binds the epitope at residues 19–26 and detects
only TAp53 (DAKO, Glostrup, Denmark). Proteins/anti-
bodies complexes were analyzed by Western blot using
rabbit polyclonal anti-p53 CM1 antibody (Novocastra,
Newcastle, UK).
Electrophoretic mobility shift assay (EMSA)
EMSA were performed as described in Verhaegh et al.,
1997 [20]. Briefly, nuclear cellular proteins of H1299-
transfected cells were extracted and incubated with mix-
ture containing 32P-radio-labeling oligonucleotide with
p53 response element consensus p53con (50-GGACATG
CCCGGGCATGTCC-30) [18]. Two antibodies were used
to shift DNA: p53 complexes, the monoclonal PAb421
antibody recognizing p53 DBD and known to stabilize
DNA: p53 complexes; and the monoclonal DO-7 anti-
body specific for the N-terminal portion of p53 protein,
recognizing TAp53 but not Δ40p53.
β-galactosidase assay
In 6-well plates, 3 × 105 H1299 and Saos-2 cells were
transfected in duplicate using Fugene transfection re-
agent with 0.5 μg/ml of pRGCΔFosLacZ plasmid (pRGC),
containing the Ribosomal Gene Cluster (RGC), which
includes three p53-binding sites with the same consen-
sus sequence as the one of p53con, upstream β-galactosidase
gene, and 2 μg/ml of pcDNA3-expression vector (empty,-TAp53, -Δ40p53). The following TAp53/Δp53 vector ra-
tios were used: 0.5/0.5 and 0.5/1.5 µ/ml. The total amount
of plasmid has been adjusted by adding pcDNA3-empty
vector to reach 2.5 μg/ml of total transfected DNA in
each condition. In addition, cell transfection efficiency
was assessed by transfecting 1 μg/ml of a GFP-
expressing vector. Twenty four hours post-transfection,
cells were harvested and β-galactosidase activity was
measured using β-galactosidase Enzyme Assay System
kit (Promega).
Western blot
Proteins were extracted using RIPA-like buffer (50 mM
Tris–HCl pH 7.4, 250mM NaCl, 0.1% SDS, 0.5% NP-40, 2
mM DTT, 1 mg/ml protease inhibitors [500 mM phenyl-
methyl-sulfonyl-fluoride (PMSF), 0.5 mg/ml leupeptin, 2
mg/ml aprotinin, 1.4 mg/ml pepstatin A]) and 30 μg of
cleared extracts were loaded on mini protean TGX 4-15%
gels (Bio-Rad, Hercules, CA, USA) and transferred using
TransBlot Turbo Transfer System (Bio-Rad). Membranes
were hybridized with several antibodies: monoclonal anti-
p53 DO-7 antibody; rabbit polyclonal anti-p53 CM1 anti-
body and monoclonal anti-p53 PAb1801 (Oncogene
Research Products, Cambridge, MA, USA), which detects
both TAp53 and Δ40p53; p53 anti-phospho-Serine 15
antibody (Cell Signaling Technology, Beverly, MA, USA);
p21WAF1 antibody (Calbiochem, Billerica, MA, USA);
Hdm2 (Calbiochem) and Ku80 (Abcam, Cambridge, UK)
or anti-actin (Santa Cruz, CA, USA) antibodies were used
as a loading control. Secondary peroxidase coupled goat
anti-mouse or -rabbit antibodies were used, followed ECL
detection according to the manufacturer’s instructions
(Amersham Biosciences AB, Buckinghamshire, UK).
Statistical analyzes
Statistical analyzes were performed using the software
GraphPad Prism (GraphPad Software, Inc) and P-values
were indicated by (*) when P < 0.05, (**) when P < 0.01
and (***) when P < 0.001.
Results
Intrinsic stability of Δ40p53 isoform
Figure 1A shows a schematic representation of TAp53
and Δ40p53 protein domains, illustrating the lack in
Δ40p53 of the N-terminal residues motifs that contain
the main transcriptional activation domain (TA, residues
1–42) as well as the amino-acid motif that binds Hdm2
(residues 17–29). Consistent with lack of targeting of
Δ40p53 by Hdm2, this isoform is more stable than full-
length p53 [9,10]. To estimate the difference in stability
between p53 and Δ40p53, we performed time-course
western-blot analysis after cycloheximide translation
block. PAb1801 antibody (a monoclonal that recognizes
residues 45–54, present in both isoforms) was used in
Figure 1 Intrinsic stability of p53 and Δ40p53 isoform. (A) Schematic representation of the domain structure of the p53 protein. The protein
contains a major transactivation domain (MTA) with Hdm2-binding site (black bar with asterisk), a minor transactivation domain (mTA), a proline-
rich domain (PXXP), a central DNA-binding domain (DBD), a C-terminal oligomerization domain (OD) and nuclear localization signals (NLS, light
grey bars). (B) Endogenous levels of expression of TAp53 and Δ40p53 detected with DO-7 and Pab1801 antibody in HCT116 p53+/+ and 21PT
cells, after cycloheximide (CHX) treatment (50 μg/ml) to block protein synthesis. Actin: loading control. Black arrow: TAp53, white arrow: Δ40p53.
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due to an insertion mutation and frameshift at position
33 which leaves intact the open reading frame of
Δ40p53, and in colorectal cancer HCT116 cells, which
express both wild-type TAp53 and Δ40p53 proteins. In
HCT116, TAp53 is significantly degraded after 30 min
whereas levels of Δ40p53 are essentially unchanged
within at least 2 hours. In 21PT, Δ40p53 shows greater
stability, with no apparent decrease in protein levels
within 8 hrs and with the protein still detectable after 20
hrs (Figure 1B). Overall, these results concur with previ-
ously published results by Yin et al., (2002), Courtois
et al., (2002) and Gosh et al., (2004) [9-11] and support
that Δ40p53 has an increased half life, which is consist-
ent with the lack of Hdm2-binding site and thus escape
from Hdm2-mediated degradation.Complex formation between TAp53 and Δ40p53
Δ40p53 conserves the oligomerization domain of p53 and
can, in principle, associate with TAp53 to form hetero-
oligomers. To determine whether the two isoforms could
complex when co-expressed in intact cells, and in which
proportion, we transfected mouse BALB/c 10.1 cells
(p53-null) with constant amounts of Δ40p53 and vari-
able amounts of full-length p53. The proteins were co-
immunoprecipitated with DO-7 (recognizing only full-
length p53), followed by western blot analysis using the
pan-isoform antibody CM1. Presence of Δ40p53 in the
immunoprecipitates demonstrated complex formation,
since DO-7 is not capable of directly immunoprecipitating
Δ40p53. Figure 2 shows that the two proteins could form
complexes. When the two isoforms were present in equal
amounts, these complexes contain equal amounts of both
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hetero-oligomers of p53 and Δ40p53 may bind to DNA,
we performed Electrophoretic Mobility Gel Shift Assays
(EMSA) using a synthetic p53 response element and ex-
tracts of H1299 cells transfected with increased levels of
Δ40p53 in the presence of constant levels of TAp53
(Figure 3). Both proteins could bind consensus DNA in
the presence of the monoclonal antibody PAb421, which
is known to stabilize and super-shift p53: DNA complexes.
In the absence of PAb421, low levels of DNA-binding
were observed for p53, but not for Δ40p53. We then used
DO-7 to perform super-super-shift experiments. Since this
antibody recognizes an epitope present in p53 but not in
Δ40p53, we reasoned that the amplitude of the super-
super-shift induced by DO-7 would correlate with the
proportion of p53 present in the hetero-oligomer. In the
absence of Δ40p53, DO-7 induced a super-super-shift
of p53: DNA complexes consistent with the binding ofFigure 2 Formation of hetero-oligomers between TAp53 and Δ40p53
10.1 cells. Immunoprecipitation was performed with DO-7 antibody (+) or
amounts of TAp53 transfected plasmid. Immunoprecipitated proteins were
immunoprecipitation is enhanced when the amount of transfected plasmid
issued from cell extract; black arrow: TAp53. (B) Immunoprecipitation of TA
performed using either TAp53 or Δ40p53 transfected plasmid. (C) Co-immu
transfected TAp53 plasmid. Same experiment of immunoprecipitation as d
1.5 μg/ml) and Δ40p53 (0.5 μg/ml). In each condition, the two p53 isoform
amount. Black arrow: TAp53; white arrow: Δ40p53.several molecules of DO-7 to the complex. Increasing the
expression of Δ40p53 relative to p53 resulted in the
formation of intermediate super-super-shifted species,
consistent with the hypothesis that hetero-oligomers
are formed by incorporating Δ40p53 that does not bind
DO-7. Overall, these experiments demonstrate that the
two forms of p53 can bind specifically to DNA and can
form mixed hetero-oligomers containing both p53 and
Δ40p53.
Effects of Δ40p53 on p53 transcriptional activity
Previous studies have shown that Δ40p53 was unable to
transactivate reporter constructs containing p53 response
elements derived from different p53 target genes [9-11].
Furthermore, expression of excess levels of Δ40p53 could
antagonize p53 transcriptional activity, thus behaving as a
potential dominant inhibitor of p53-dependent gene re-
gulation. However, these experiments were performed in. (A) Immunoprecipitation of TAp53 using DO-7 antibody in BALB/c
without DO-7 antibody as a negative control (−) using increasing
analyzed by immunoblotting using CM1 polyclonal antibody. TAp53
is increased. pcDNA3: empty vector; input: unprecipitated proteins
p53 or Δ40p53 using DO-7 antibody. Immunoprecipitation was
noprecipitation of TAp53 and Δ40p53 using different amount of
escribed in (A) and (B), using co-transfection of both TAp53 (0.5 and
s interact but in particular when they are expressed in the same
Figure 3 DNA-binding activity of TAp53 and Δ40p53. Electrophoretic mobility shift assay (EMSA) detecting DNA-binding activity. p53-null
H1299 cells were co-transfected with a constant amount of pcDNA3-TAp53 plasmid (0.5 μg/ml) in the presence of increasing amounts of
pcDNA3-Δ40p53 plasmid (0.5 and 1.5 μg/ml). Nuclear extracts were incubated with a 32P-labeled p53con oligonucleotide, with or without PAb421,
which stabilizes and super-shifts p53: DNA complexes. DO-7 induces a super-super-shift of p53/DNA complexes. DNA: p53 shifts, DNA: p53:
PAb421 super-shifts, DNA: p53:PAb421:DO-7 super-super-shifts are indicated by black arrows.
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levels of p53 itself [9,11]. To address the effect of Δ40p53
when expressed at low levels relative to TAp53, we co-
transfected either H1299 or Saos-2 cells with TAp53, va-
riable amounts of Δ40p53, and a β-galactosidase p53
reporter gene. Results (Figure 4) show that Δ40p53 had no
measurable transcriptional activity on its own butFigure 4 Effects of Δ40p53 on p53 transcriptional activity. (A) Inhibito
TAp53 in H1299 cells. The transactivation activity of p53 isoforms was meas
as relative β-galactosidase activity induced by TAp53 expressed alone at 0.5
analyzed by immunoblotting using DO-7 and PAb1801 antibodies (bottom
expression increased with the increase of amount of transfected plasmid a
experiment as defined in (A), but in Saos-2 cells. Each error-bar represents
performed in triplicate. Ku80: loading control. *P < 0.05 and **P < 0.01 calcumodulated the transcriptional activity of TAp53 with dif-
ferent effects in the two cell lines. In H1299, Δ40p53
appeared to inhibit TAp53 transcriptional activity in an in-
cremental manner, depending upon the dosage of Δ40p53.
In Saos-2 cells, inhibition of p53 transcriptional activity
towards β-galactosidase reporter was observed only with
higher amounts of Δ40p53, whereas the transcriptionalry effect of Δ40p53 on transcriptional activity of increasing amount of
ured towards the p53 response element of RGC plasmid and plotted
μg/ml (top panel). TAp53 and Δ40p53 protein expressions were
panel). The induction of p21WAF1 was also analyzed. Δ40p53
nd TAp53 was constantly expressed. (B) Same reporter assay
the standard deviation of three independent experiments, each
lated by t-test. Black arrow: TAp53; white arrow: Δ40p53.
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Δ40p53 was expressed at lower levels, although this
increase was not statistically significant. Of note, levels of
p21WAF1 protein, which may be considered as readout for
p53 transcriptional activity, were strongly reduced by ex-
pression of Δ40p53 in H1299 cells, whereas they were at
least partially maintained in Saos-2 cells. This observation
further supports that the effects of Δ40p53 on TAp53 ac-
tivity differ between H1299 and Saos-2 cells.
Inhibition curves of p53 transcriptional activity by Δ40p53
The results above suggest that in Saos-2 cells, inhibition
of TAp53 transcriptional activity by Δ40p53 does not fol-
low a linear curve determined by oligomerization between
p53 isoforms. To test this hypothesis, we have used the
strategy developed by Chan et al. (2004) to investigate
how many mutant p53 molecules were needed to inacti-
vate a p53 tetramer [21]. Assuming that the probability of
formation of tetramers containing 1, 2 or 3 subunits of
Δ40p53 is dependent upon the relative levels of expression
of each of the proteins (Figure 5A), we have predicted the
theoretical inhibition curves of TAp53 activity by Δ40p53
and we have compared these predictions to actual levels
of expression of the TAp53-dependent β-galactosidase re-
porter in H1299 and in Saos-2 cells at three differentFigure 5 Predictive inhibition capacity of Δ40p53 isoform. (A) Mathem
containing different numbers of TAp53 and Δ40p53 monomers (adapted fr
different tetramers are indicated, where r is the ratio (concentration of Δ40
(B) Prediction of TAp53/Δ40p53 hetero-tetramer formation based on β-gala
to the proportions defined in (A). The predicted inhibition curves (dotted l
tetramers shown in (A). Transcriptional activities measured using a β-galact
triangles represent the different values obtained in six independent experim
dotted line, the average curve. Blue circles represent the different values ob
blue crosses joined by dotted line, the average curve. P-values are given fo
***P < 0.001.TAp53/Δ40p53 ratios (Figure 5B). Results show that in-
hibition curves did not fulfill the theoretical model of
dose-dependent hetero-tetramer formation. In addition,
the curves were strikingly different between the two cell
lines. In H1299 cells, the inhibition of TAp53 activity by
Δ40p53 was effective at low levels of Δ40p53, consistent
with the prediction curve in which 1 subunit of Δ40p53
can inhibit a tetramer in which the 3 other subunits are
TAp53. However, the effectiveness of this inhibition de-
creased with amounts of Δ40p53. When the two proteins
were transfected at 1:1 ratio, the inhibition curve was
roughly consistent with a pattern in which 2 subunits of
Δ40p53 were required to inhibit one tetramer. At higher
amounts of Δ40p53 relative to TAp53, the inhibition curve
tended towards the pattern in which 1 subunit of TAp53
is sufficient to maintain transcriptional activity. In Saos-2
cells, expression of Δ40p53 relative to TAp53 at ratios
below or equal 1:1 was led to levels of transcriptional ac-
tivity that were maintained or even slightly increased,
while in the higher ratio of 3:1, the inhibition was as ef-
fective as in H1299 cells. Thus, Δ40p53 appears to have
paradoxical effects on the transcriptional activity of p53,
suggesting that in addition to interfering with p53 through
oligomerization, Δ40p53 may also modify other parame-
ters that determine p53-dependent gene expression in a
cell-dependent manner.atical approach to analyze probabilities of the tetramer formation,
om [21]). The equations defining the probabilities (P) of forming
p53/concentration of TAp53). p53 denotes TAp53 and Δ40, Δ40p53.
ctosidase assay results using cells transfected with vectors according
ines) were calculated from the probability of forming the different
osidase reporter gene as described in Figure 4 were plotted. Green
ents done in triplicate in H1299 cells and green crosses joined by
tained in three independent experiments done in Saos-2 cells and
r the comparison between H1299 and Saos2 cells. *P < 0.05 and
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degradation in Saos-2 cells
One mechanism by which Δ40p53 may influence the tran-
scriptional activity of TAp53 is through modulation of p53
protein stability and, in particular, modulation of Hdm2-
mediated degradation. Indeed, Δ40p53 is intrinsically more
stable than TAp53 due to absence of Hdm2-binding cap-
acity and it is possible that, depending upon cell context,
the Δ40p53 isoform may confer an increased stability to
mixed oligomers containing both TAp53 and Δ40p53. This
hypothesis was tested by analyzing the levels of TAp53 in
Saos-2 co-transfected with TAp53, Δ40p53 and Hdm2.
Figure 6 shows that co-transfection of TAp53 together with
Hdm2 resulted in the almost complete disappearance of
TAp53, in agreement with enhanced degradation of the
protein. As expected, levels of Δ40p53 were not decreased
by co-transfection with Hdm2. Co-transfection of the three
factors resulted in the maintenance of detectable levels of
TAp53 with increased phosphorylation on serine 15 even
in the presence of Hdm2, compatible with protection by
Δ40p53 from Hdm2-dependent degradation. Thus, in
Saos-2 cells, Δ40p53 appears to be capable of modulating
the stability of TAp53, leading to the persistence in cells of
higher levels of TAp53 bearing phospho-serine 15, a hall-
mark of p53 activation.
Discussion
Δ40p53 was the first identified N-terminal isoform of
p53 and there is evidence from animal model systemsFigure 6 Δ40p53 protects TAp53 from Hdm2-mediated
degradation in Saos-2 cells. TAp53 plasmid was co-transfected
with Δ40p53 and Hdm2 in Saos-2 cells. The level of expression of
the proteins was analyzed by immunoblotting using DO-7 and
PAb1801 antibodies for the detection of TAp53 and Δ40p53. The co-
transfection of TAp53 together with Hdm2 results in the
degradation of TAp53. Levels of Δ40p53 are not decreased by co-
transfection with Hdm2. Co-transfection of the three factors results
in the maintenance of detectable levels of TAp53 with increased
phosphorylation on Serine 15 even in the presence of Hdm2.that it exerts a strong regulatory effect on the biological
activity of the p53 protein [13-15]. In this study, we have
used in vitro approaches to show that Δ40p53 can form
mixed oligomers with TAp53 that can bind to specific
DNA and modulate the capacity of p53 to activate a
generic reporter gene driven by a standard p53 response
element. This modulation did not follow a proportional
dose–response according to the relative expression of
TAp53 and Δ40p53. In H1299 cells, co-expression of the
two proteins induced a decrease in the transcriptional
activity, but the amplitude of the effect varied depending
upon the predicted composition of the hetero-tetramer.
In Saos-2, a paradoxical effect was observed, with no de-
crease and possibly a small increase in transcriptional
activity for hetero-tetramers predicted to contain 1 or 2
monomers of Δ40p53, and a strong decrease for hetero-
tetramers predicted to contain 3 monomers of Δ40p53.
These different effects suggest that Δ40p53 may exert
subtle modulation on p53 activity, in particular in the
range of expression levels that are generally observed in
non-transfected cells, where Δ40p53 is expressed at
lower or, at the most, equal levels to TAp53.
The differences between the two cell lines can be ratio-
nalized by considering that Δ40p53 may alter the dynam-
ics of hetero-tetramers in two opposite ways. First, it may
alter the binding to component of the basal transcription
machinery, thus decreasing transcriptional activation. Sec-
ond, it may interfere with the binding of Hdm2 to the
hetero-tetramer, thus modulating its subsequent post-
translational modification, its nuclear export and its deg-
radation through the proteasome machinery. Supporting
this view, we show that, in Saos-2 cells, Δ40p53 could at
least partially protect TAp53 from Hdm2-mediated deg-
radation. The differences between the two cell lines with
respect to the effect of Δ40p53 on the transcriptional
activity of TAp53 may be due to multiple cell-specific
mechanisms, including levels of expression of Hdmx,
which co-regulates p53 stability together with Hdm2, as
well as Hdm2-independent effects. Of note, p53 mono-
mers are resistant to Hdm2-mediated degradation in vitro
and in intact cells, despite the presence of Hdm2 binding
sites on each p53 monomer. Dimerization, but not tetra-
merization, is required for Hdm2-dependent degradation [22].
The observation that Δ40p53 may exert, in defined
condition and cell context, a positive effect on p53 tran-
scriptional activity, may account for some of the bio-
logical characteristics of animal models expressing this
isoform. Both in the mouse expressing p44, an equiva-
lent to Δ40p53, and in Zebrafish, expression of Δ40p53
alone in a p53-null background does not significantly
affect the phenotype [13-15]. In contrast, dramatic ef-
fects are seen when both TAp53 and Δ40p53 are co-
expressed, and these effects are consistent with an in-
crease and modulation of p53-dependent suppressive
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co-expressing TAp53 and Δ40p53 do not show a tumor-
prone phenotype attributable to inhibition of p53 activity
[13,14]. In contrast, they show increased organismal and
tissular senescence attributable to decline in stem cell re-
newal and in general fitness. In Zebrafish, co-expression
of the two proteins lead to developmental defects attribut-
able to hypoplasia, malformation of the head, eyes and
somites, a phenotype which is also compatible with en-
hanced, rather than decrease, p53 suppressive activity
[15]. These effects are rescued by co-expression of a
dominant-negative p53 mutant, suggesting that they are
indeed dependent upon increased p53 suppressive activity.
Overall, our observations shed a new light on a possible
role of Δ40p53 in the regulation of p53 activity in stem
and progenitor cells, contributing to either enhance or in-
hibit p53 function in a manner which is exquisitely regu-
lated by the relative levels of each isoform and their
interrelations with p53 regulatory systems such as Hdm2/
Hdmx.
A recent study by Ungewitter and Scrable (2010) has
determined that Δ40p53 was the major p53 isoform
expressed in mouse embryonic stem cells (ESC) as well
as during the early stages of embryogenesis [23]. They
further showed that altering the dose of Δ40p53 had a
strong impact on the maintenance of the ESC state.
Haploinsufficiency for Δ40p53 (resulting in lower levels
of this isoform) caused loss of pluripotency and changes
in cell-cycle with the acquisition of a cell-cycle profile
characteristic of the one of somatic, differentiated cells.
By contrast, increased dosage of Δ40p53 caused an ex-
tension of pluripotency and prevented progression to a
more differentiated state. These observations suggest that
in mouse embryonic cells, high levels of expression of
Δ40p53 may prevent the activation of a mechanism of exit
from ESC status into a somatic cell status. Within such a
context, our results of a dual effect of Δ40p53 on TAp53
activity suggest that Δ40p53 might play a subtle role in
regulating the transition from ESC to somatic cell status.
At high levels, Δ40p53 may maintain pluripotency by neu-
tralizing p53. As cells shift towards a somatic status, de-
creasing levels of Δ40p53 may contribute to activate
TAp53 and to switch on a mechanism of progression out
of ESC status towards differentiation. Further studies are
needed to determine whether presence of defined levels of
Δ40p53 may be required to adequately drive the exit from
ESC status during embryogenesis.
It is recognized that this in vitro study has a number
of limitations. First, the effects have been studied using
only one type of consensus p53 RE and reporter gene.
Given the wide repertoire of p53 RE and their capacity
to respond in a different way to p53 activation, it is
plausible that modulation of transactivation by Δ40p53
may have different effects on different p53 targets.Second, although implicating Hdm2 as an essential regu-
lator of the activity of TAp53/Δ40p53 hetero-oligomers,
our study has not quantified variations in the binding of
Hdm2 to different types of hetero-oligomers and has not
clearly identified the consequences on p53 protein sta-
bility. Third, Δ40p53 is not the sole N-terminal isoform
which may regulate p53 activity. In particular, Δ133p53
(which lacks the N-terminal transactivation domain, the
proline-rich domain and the proximal part of the DNA-
binding domain) also retains the oligomerization domain
and may interfere as third partner in hetero-oligomers
containing TAp53 and Δ40p53. We have previously
shown that, in contrast to Δ40p53, Δ133p53 does not
bind to DNA and prevents TAp53 to recognize its cog-
nate response element. Recent studies have proposed
that Δ133p53 may play a role as enhancer of p53-
dependent cell senescence [24].
Conclusion
Overall, our results add to the complex picture of interac-
tions between p53 and its N-terminal isoforms to suggest
that, in defined conditions, these isoforms may either en-
hance or decrease the basal level of p53 activity, thus con-
tributing to set a threshold for p53-dependent responses
to a wide variety of endogenous or exogenous stimuli.
These results provide molecular insights to interpret the
biological phenotypes characterized by growth-suppressive
effects in animal models co-expressing roughly similar
levels of p53 and Δ40p53.
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